Multi-targeted molecular therapeutic approach in aggressive neuroblastoma: The effect of Focal Adhesion Kinase-Src-Paxillin system

Expert Opinion on Therapeutic Targets

Volumn 18, Issue 12, 2014, Pages 1395-1406

  Kratimenos, Panagiotis ^a   Koutroulis, Ioannis ^b   Marconi, Dante ^a   Syriopoulou, Vasiliki ^c   Delivoria Papadopoulos, Maria ^a   Chrousos, George P ^c   Theocharis, Stamatios ^c  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b ST CHRISTOPHER'S HOSPITAL FOR CHILDREN   (United States)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Focal adhesion kinase; Neuroblastoma; Paxillin; Small molecule inhibitors; Src

Indexed keywords

16 HYDROXYCLERODA 3,13 DIEN 16,15 OLIDE; 2 [5 CHLORO 2 (2 METHOXY 4 MORPHOLINOANILINO) 4 PYRIMIDINYLAMINO] N METHYLBENZAMIDE; 4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; ALVESPIMYCIN; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CONSTITUTIVE ANDROSTANE RECEPTOR; DOXORUBICIN; FOCAL ADHESION KINASE; FOCAL ADHESION KINASE INHIBITOR; FRIZZLED PROTEIN; GSK 2256098; NUTLIN 3; NVP TAE 226; OKADAIC ACID; PANOBINOSTAT; PAXILLIN; PF 04554878; PF 562271; PF 573228; PROTEIN MDM2; PROTEIN TYROSINE KINASE; RECEPTOR FOR ACTIVATED C KINASE 1; STAT3 PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VERRUCARIN A; VORINOSTAT; Y 15; [2 (4 TERT BUTYL 2 ETHOXYPHENYL) 4,5 BIS(4 CHLOROPHENYL) 4,5 DIHYDRO 4,5 DIMETHYL 1H IMIDAZOL 1 YL][4 [3 (METHYLSULFONYL)PROPYL] 1 PIPERAZINYL]METHANONE;

ACTIN FILAMENT; ANTIPROLIFERATIVE ACTIVITY; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; CELL ADHESION; CELL MOTILITY; CELL PROLIFERATION; CELL TRANSFORMATION; DRUG STRUCTURE; DRUG TARGETING; FOCAL ADHESION; HUMAN; MALIGNANT TRANSFORMATION; METASTASIS INHIBITION; MOLECULARLY TARGETED THERAPY; MULTIDRUG RESISTANCE; NEUROBLASTOMA; NONHUMAN; ONCOGENE C MYB; PHASE 1 CLINICAL TRIAL (TOPIC); PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTO ONCOGENE; REGULATORY MECHANISM; REVIEW; TUMOR GROWTH;

EID: 84964292608     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2014.952280     Document Type: Review

References (82)

1. Hayat MA. Pediatric cancer diagnosis, therapy, and prognosis. Volume 4 Springer Verlag, New Jersey, USA; 2013. ISBN-10: 9400765908
2. Hayat MA. Neuroblastoma diagnosis, therapy, and prognosis. Springer Verlag, New Jersey, USA; 2012. ISBN-10: 9400724179
3. Maris JM, Matthay KK. Molecular biology of neuroblastoma. J Clin Oncol 1999;17:2264-79
4. Chen CS, Alonso JL, Ostuni E, et al. Cell shape provides global control of focal adhesion assembly. Biochem Biophys Res Commun 2003;307:355-61
5. Matsuura S, Kondo S, Suga K, et al. Expression of focal adhesion proteins in the developing rat kidney. J Histochem Cytochem 2011;59:864-74
6. Zaidel-Bar R, Cohen M, Addadi L, et al. Hierarchical assembly of cell matrix adhesion complexes. Biochem Soc Trans 2004;32:416-20
7. Riveline D, Zamir E, Balaban NQ, et al. Focal contacts as mechanosensors: externally applied local mechanical force induces growth of focal contacts by an mDia1-dependent and ROCKindependent mechanism. J Cell Biol 2001;153:1175-86
8. Dunn KB, Heffler M, Golubovskaya VM. Evolving therapies and FAK inhibitors for the treatment of cancer. Anticancer Agents Med Chem 2010;10:722-34
9. Plaza-Menacho I, Morandi A, Mologni L, et al. Focal adhesion kinase (FAK) binds RET kinase via its FERM domain, priming a direct and reciprocal RET-FAK transactivation mechanism. J Biol Chem 2011;286:17292-302
10. Zang XP, Pento JT, Tari AM. Wilms' tumor 1 protein and focal adhesion kinase mediate keratinocyte growth factor signaling in breast cancer cells. Anticancer Res 2008;28(1A):133-7
11. Bertolucci CM, Guibao CD, Zheng J. Structural features of the focal adhesion kinase-paxillin complex give insight into the dynamics of focal adhesion assembly. Protein Sci 2004;14:644-52
12. Golubovskaya VM, Finch R, Cance WG. Direct interaction of the N-terminal domain of focal adhesion kinase with the N-terminal transactivation domain of p53. J Biol Chem 2005;280(26):25008-21
13. Chatzizacharias NA, Kouraklis GP, Theocharis SE. The role of focal adhesion kinase in early development. Histol Histopathol 2010;25:1039-55
14. Jones SN, Hancock AR, Vogel H, et al. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc Natl Acad Sci USA 1998;95:15608-12
15. Bond GL, Hu W, Bond EE, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004;119:591-602
16. Terzian T, Wang Y, Van Pelt CS, et al. Haploinsufficiency of Mdm2 and Mdm4 in tumorigenesis and development. Mol Cell Biol 2007;27:5479-85
17. Gamble LD, Kees UR, Tweddle DA, et al. MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63. Oncogene 2012;31:752-63
18. Chatzizacharias NA, Kouraklis GP, Theocharis SE. Clinical significance of FAK expression in human neoplasia. Histol Histopathol 2008;23:629-50
19. Ho WL, Che MI, Chou CH, et al. B3GNT3 expression suppresses cell migration and invasion and predicts favorable outcomes in neuroblastoma. Cancer Sci 2013;104:1600-8
20. Chen YX, Chen XW, Li CG, et al. Effect of tumor gangliosides on tyrosine phosphorylation of p125FAK in platelet adhesion to collagen. Oncol Rep 2013;29:343-8
21. Lee S, Qiao J, Paul P, et al. FAK is a critical regulator of neuroblastoma liver metastasis. Oncotarget 2012;3:1576-87
22. Gupta A, Bisht B, Dey CS. Focal adhesion kinase negatively regulates neuronal insulin resistance. Biochim Biophys Acta 2012;1822:1030-7
23. Maman S, Edry-Botzer L, Sagi-Assif O, et al. The metastatic microenvironment: lung-derived factors control the viability of neuroblastoma lung metastasis. Int J Cancer 2013;133:2296-306
24. Waters AM, Beierle EA. The interaction between FAK, MYCN, p53 and Mdm2 in neuroblastoma. Anticancer Agents Med Chem 2014;14:46-51
25. Beierle E, Trujillo A, Nagaram A, et al. N-MYC regulates focal adhesion kinase expression in human neuroblastoma. J Biol Chem 2007;282:12503-16
26. Beierle E, Massoll N, Hartwich J, et al. Focal adhesion kinase expression in human neuroblastoma: immunohistochemical and real-time PCR analyses. Clin Cancer Res 2008;14:3299-305
27. Beierle E, Ma X, Trujillo A, et al. Inhibition of focal adhesion kinase and src increases detachment and apoptosis in human neuroblastoma cell lines. Mol Carcinog 2010;49:224-34
28. Kim B, van Golen CM, Feldman EL. Degradation and dephosphorylation of focal adhesion kinase during okadaic acid-induced apoptosis in human neuroblastoma cells. Neoplasia 2003;5(5):405-16
29. Thiyagarajan V, Lin SH, Chia YC, et al. A novel inhibitor, 16-hydroxy-cleroda-3,13-dien-16,15-olide, blocks the autophosphorylation site of focal adhesion kinase (Y397) by molecular docking. Biochim Biophys Acta 2013;1830:4091-101
30. Falsone SF, Leptihn S, Osterauer A, et al. Oncogenic mutations reduce the stability of Src kinase. J Mol Biol 2004;344:281-91
31. Eliceiri BP, Paul R, Schwartzberg PL, et al. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol Cell 1999;4:915-24
32. Cohen GB, Ren R, Baltimore D. Modular binding domains in signal transduction proteins. Cell 1995;80:237-48
33. Thomas SM, Brugge JS. Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 1997;13:513-609
34. Roskoski R Jr. Src protein-tyrosine kinase structure and regulation. Biochem Biophys Res Commun 2004;324:1155-64
35. Liu D, Xu R, Cowburn D. Segmental isotopic labeling of proteins for nuclear magnetic resonance. Methods Enzymol 2008;462:151-75
36. Cooper JA, Gould KL, Cartwright CA, et al. Tyr527 is phosphorylated in pp60c-src: implications for regulation. Science 1986;231:1431-4
37. Okada M, Nakagawa H. A protein tyrosine kinase involved in regulation of pp60c-src function. J Biol Chem 1989;264:20886-93
38. Nada S, Okada M, MacAuley A, et al. Cloning of a complementary DNA for a protein-tyrosine kinase that specifically phosphorylates a negative regulatory site of p60c-src. Nature 1991;351:69-72
39. Oneyama C, Hikita T, Nada S, et al. Functional dissection of transformation by c-Src and v-Src. Genes Cells 2008;13:1-12
40. Brown MT, Cooper JA. Regulation, substrates and functions of src. Biochim Biophys Acta 1996;1287:121-49
41. Lu F, Zhang C, Wu WJ, et al. RACK1 downregulation suppresses migration and proliferation of neuroblastoma cell lines. Oncol Rep 2012;27:1646-52
42. Martin GS. The hunting of the Src. Nat Rev Mol Cell Biol 2001;2:467-75
43. Yeatman TJ. A renaissance for SRC. Nat Rev Cancer 2004;4(6):470-80
44. Ohira M, Morohashi A, Nakamura Y, et al. Neuroblastoma oligo-capping cDNA project: toward the understanding of the genesis and biology of neuroblastoma. Cancer Lett 2003;197(1-2):63-8
45. Takagi D, Tatsumi Y, Yokochi T, et al. Novel adaptor protein Shf interacts with ALK receptor and negatively regulates its downstream signals in neuroblastoma. Cancer Sci 2013;104:563-72
46. Tiffon C, Adams J, van der Fits L, et al. The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells. Br J Pharmacol 2011;162:1590-602
47. Ko KS, Steffey ME, Brandvold KR, et al. Development of a chimeric c-Src kinase and HDAC inhibitor. ACS Med Chem Lett 2013;4:779-83
48. Yan F, Yu Y, Chow DC, et al. Identification of verrucarin A as a potent and selective steroid receptor coactivator-3 small molecule inhibitor. PLoS One 2014;9:e95243
49. Tumbarello DA, Brown MC, Turner CE. The paxillin LD motifs. FEBS Lett 2002;513:114-18
50. Thomas JW, Cooley MA, Broome JM, et al. The role of focal adhesion kinase binding in the regulation of tyrosine phosphorylation of paxillin. J Biol Chem 1999;274:36684-92
51. Bellis SL, Miller JT, Turner CE. Characterization of tyrosine phosphorylation of paxillin in vitro by focal adhesion kinase. J Biol Chem 1995;270:17437-41
52. Stiegler AL, Draheim KM, Li X, et al. Structural basis for paxillin binding and focal adhesion of beta-parvin. J Biol Chem 2012;287:32566-77
53. Brown MC, Cary LA, Jamieson JS, et al. Src and FAK kinases cooperate to phosphorylate paxillin kinase linker, stimulate its focal adhesion localization, and regulate cell spreading and protrusiveness. Mol Biol Cell 2005;16:4316-28
54. Giancotti FG. A structural view of integrin activation and signaling. Dev Cell 2003;4(2):149-51
55. Brown MC, Turner CE. Paxillin: adapting to change. Physiol Rev 2004;84(4):1315-39
56. Mitra SK, Hanson DA, Schlaepfer DD. Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol 2005;6(1):56-68
57. Schaller MD, Hildebrand JD, Shannon JD, et al. Autophosphorylation of the focal adhesion kinase, pp125FAK, directs SH2-dependent binding of pp60src. Mol Cell Biol 1994;14(3):1680-8
58. Playford MP, Vadali K, Cai X, et al. Focal adhesion kinase regulates cell-cell contact formation in epithelial cells via modulation of Rho. Exp Cell Res 2008;314(17):3187-97
59. Lamorte L, Rodrigues S, Sangwan V, et al. Crk associates with a multimolecular Paxillin/GIT2/beta-PIX complex and promotes Rac-dependent relocalization of Paxillin to focal contacts. Mol Biol Cell 2003;14(7):2818-31
60. Petit V, Boyer B, Lentz D, et al. Phosphorylation of tyrosine residues 31 and 118 on paxillin regulates cell migration through an association with CRK in NBT-II cells. J Cell Biol 2000;148(5):957-70
61. Brábek J, Hanks SK. Assaying protein kinase activity. Methods Mol Biol 2004;284:79-90
62. Schlaepfer DD, Mitra SK. Multiple connections link FAK to cell motility and invasion. Curr Opin Genet Dev 2004;14(1):92-101
63. Liang W, Ren K, Liu F, et al. Periodic mechanical stress stimulates the FAK mitogenic signal in rat chondrocytes through ERK1/2 activity. Cell Physiol Biochem 2013;32(4):915-30
64. Xu L, Wang X, Wan J, et al. Sonic Hedgehog pathway is essential for neuroblastoma cell proliferation and tumor growth. Mol Cell Biochem 2012;364(1-2):235-41
65. Cantilena S, Pastorino F, Pezzolo A, et al. Frizzled receptor 6 marks rare, highly tumourigenic stem-like cells in mouse and human neuroblastomas. Oncotarget 2011;2(12):976-83
66. Yi B, Yang J, Wang L. The growth inhibitory effect of 17-DMAG on ALK and MYCN double-positive neuroblastoma cell line. Tumour Biol 2014;35(4):3229-35
67. Li D, Mei H, Qi M, et al. FOXD3 is a novel tumor suppressor that affects growth, invasion, metastasis and angiogenesis of neuroblastoma. Oncotarget 2013;4(11):2021-44
68. Bozzo C, Defilippi P, Silengo L, et al. Role of tyrosine phosphorylation in matrix-induced neurite outgrowth in human neuroblastoma cells. Exp Cell Res 1994;214:313-22
69. Leventhal P, Shelden E, Kim B, et al. Tyrosine phosphorylation of paxillin and focal adhesion kinase during insulin-like growth factor-I-stimulated lamellipodial advance. J Biol Chem 1997;272:5214-18
70. Lagodny J, Jüttner E, Kayser G, et al. Lymphangiogenesis and its regulation in human neuroblastoma. Biochem Biophys Res Commun 2007;352:571-7
71. van Iterson V, Leidenius M, von Smitten K, et al. VEGF-D in association with VEGFR-3 promotes nodal metastasis in human invasive lobular breast cancer. Am J Clin Pathol 2007;128:759-66
72. Beierle E, Dai W, Langham MR Jr, et al. VEGF receptors are differentially expressed by neuroblastoma cells in culture. J Pediatr Surg 2003;38:514-21
73. Beierle E, Dai W, Langham MR Jr, et al. Expression of VEGF receptors in cocultured neuroblastoma cells. J Surg Res 2004;119:56-65
74. Stewart JE, Ma X, Megison M, et al. Inhibition of FAK and VEGFR-3 binding decreases tumorigenicity in neuroblastoma. Mol Carcinog 2013. [Epub ahead of print]
75. Stanton L, Schwab M, Bishop J. Nucleotide sequence of the human Nmyc gene. Proc Natl Acad Sci USA 1986;83:1772-86
76. Brodeur G, Seeger R, Schwab M, et al. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984;224:1121-4
77. Xu W, Harrison SC, Eck MJ. Three-dimensional structure of the tyrosine kinase c-Src. Nature 1997;385:595-602
78. Megison ML, Stewart JE, Nabers HC, et al. FAK inhibition decreases cell invasion, migration and metastasis in MYCN amplified neuroblastoma. Clin Exp Metastasis 2013;30:555-68
79. Kurenova E, Hunt D, He D, et al. Small molecule chloropyramine hydrochloride (C4) targets the binding site of focal adhesion kinase and vascular endothelial growth factor receptor 3 and suppresses breast cancer growth in vivo. J Med Chem 2009;52:4716-24
80. Molckovsky A, Siu LL. First-in-class, first-in-human phase I results of targeted agents: highlights of the 2008 American society of clinical oncology meeting. J Hematol Oncol 2008;1:20
81. Schultze A, Fiedler W. Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer. Expert Opin Investig Drugs 2010;19:777-88
82. Delivoria-Papadopoulos M, Malaeb S. Effect of concurrent administration of apoptotic inhibitors and hypothermia on post hypoxic cerebral injury in the newborn. Hell J Nucl Med 2014;17(Suppl 1):24-5